Genetic studies have disclosed mutations and subsequent activation of the phosphoinositide 3-kinase/AKT (PI3K/AKT) and the mitogen activated protein kinase (MAPK) signaling pathways in RMS that contribute to tumor growth, cellular proliferation and invasion and may affect patients’ prognosis and outcome [5]. This evidence concerns the gene AKT1 and neoplasm.